Eliminating biofilm from ureteral stents: the holy grail

被引:17
作者
Denstedt, John D. [1 ,2 ]
Cadieux, Peter A. [1 ,2 ,3 ]
机构
[1] Lawson Hlth Res Inst, London, ON, Canada
[2] Univ Western Ontario, Dept Surg, Div Urol, Schulich Sch Med & Dent, London, ON N6A 3K7, Canada
[3] Univ Western Ontario, Dept Microbiol & Immunol, Schulich Sch Med & Dent, London, ON N6A 3K7, Canada
关键词
biofilm; ureteral stent; urinary tract infection; QUORUM-SENSING INHIBITOR; RESISTANT STAPHYLOCOCCAL INFECTIONS; URINARY-TRACT PATHOGENS; BACTERIAL ADHESION; PROTEUS-MIRABILIS; TRICLOSAN; SILVER; PREVENTION; CATHETERS; HYDROGEL;
D O I
10.1097/MOU.0b013e328323d6d2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Biofilms continue to be a major limiting factor in the long-term use of ureteral stents, promoting the development of chronic infections and antibiotic resistance and encrustation. Apart from stent removal in conjunction with antibiotic therapy, there is currently no treatment proven successful for completely eradicating a biofilm-related infection, highlighting the need for continued research in this area. Recent findings Research continues to focus mainly on biofilm prevention, specifically the development of novel coatings comprising antibacterial, antifouling or bacterial signalling compounds. Notably, all three strategies have generated candidate coatings showing recent success both in vitro and in vivo. Summary Despite the current lack of a completely biofilm-resistant device, coating or treatment strategy, continued research into the causation of bacterial biofilm formation and the continued development of novel antibacterial, antifouling and antibiofilm compounds is promising. Future work should be aimed at more rigorous testing of candidate coatings from both physical and bacterial challenge standpoints as well as increased in-vivo investigation via clinical trials.
引用
收藏
页码:205 / 210
页数:6
相关论文
共 59 条
[1]   Prevention of Staphylococcal biofilm-associated infections by the quorum sensing inhibitor RIP [J].
Balaban, N ;
Stoodley, P ;
Fux, CA ;
Wilson, S ;
Costerton, JW ;
Dell'Acqua, G .
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2005, (437) :48-54
[2]   Triclosan: Applications and safety [J].
Bhargava, HN ;
Leonard, PA .
AMERICAN JOURNAL OF INFECTION CONTROL, 1996, 24 (03) :209-218
[3]   Silver against Pseudomonas aeruginosa biofilms [J].
Bjarnsholt, Thomas ;
Kirketerp-Moller, Klaus ;
Kristiansen, Soren ;
Phipps, Richard ;
Nielsen, Anne Kirstine ;
Jensen, Peter Ostrup ;
Hoiby, Niels ;
Givskov, Michael .
APMIS, 2007, 115 (08) :921-928
[4]   The role of quorum sensing in the pathogenicity of the cunning aggressor Pseudomonas aeruginosa [J].
Bjarnsholt, Thomas ;
Givskov, Michael .
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2007, 387 (02) :409-414
[5]   Epigallocatechin gallate inhibits biofilm formation by ocular staphylococcal isolates [J].
Blanco, AR ;
Sudano-Roccaro, A ;
Spoto, GC ;
Nostro, A ;
Rusciano, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (10) :4339-4343
[6]  
CADIEUX PA, 2008, J ENDOUROL
[7]   Triclosan loaded ureteral stents decrease proteus mirabilis 296 infection in a rabbit urinary tract infection model [J].
Cadieux, Peter A. ;
Chew, Ben H. ;
Knudsen, Bodo E. ;
DeJong, Kathy ;
Rowe, Elaine ;
Reid, Gregor ;
Denstedt, John D. .
JOURNAL OF UROLOGY, 2006, 175 (06) :2331-2335
[8]   Heparin coating on ureteral Double J stents prevents encrustations:: An in vivo case study [J].
Cauda, Furio ;
Cauda, Valentina ;
Fiori, Cristian ;
Onida, Barbara ;
Garrone, Edoardo .
JOURNAL OF ENDOUROLOGY, 2008, 22 (03) :465-472
[9]   The biology and future prospects of antivirulence therapies [J].
Cegelski, Lynette ;
Marshall, Garland R. ;
Eldridge, Gary R. ;
Hultgren, Scott J. .
NATURE REVIEWS MICROBIOLOGY, 2008, 6 (01) :17-27
[10]   In-vitro activity of triclosan-eluting ureteral stents against common bacterial uropathogens [J].
Chew, Ben H. ;
Cadieux, Peter A. ;
Reid, Gregor ;
Denstedt, John D. .
JOURNAL OF ENDOUROLOGY, 2006, 20 (11) :949-958